EMA Authorised: Noxafil (posaconazole) — Merck Sharp and Dohme B.V

View source ↗

Summary

The EMA has granted marketing authorization for Noxafil (posaconazole) by Merck Sharp & Dohme B.V. for the treatment and prevention of fungal infections includi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aspergillosis
• Candidiasis
• Coccidioidomycosis

Drugs mentioned

• NOXAFIL (POSACONAZOLE)

Snippet

Status: Authorised. Therapeutic area: Candidiasis;Mycoses;Coccidioidomycosis;Aspergillosis. MAH: Merck Sharp and Dohme B.V. Decision date: 05/03/2026